Walker Neal's Insider Trades & SAST Disclosures
Walker Neal's most recent trade in Aclaris Therapeutics Inc was a trade of 9,467 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Walker Neal.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 9,467 | 1,476,374 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 9,467 | 9,467 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.48 per share. | 01 Apr 2025 | 3,042 | 1,473,332 (3%) | 0% | 1.5 | 4,502 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 9,466 | 18,934 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 9,466 | 1,470,184 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.99 per share. | 01 Mar 2025 | 3,277 | 1,466,907 (3%) | 0% | 2.0 | 6,521 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 888,800 | 888,800 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 253,900 | 253,900 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 9,467 | 1,464,277 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 9,467 | 28,400 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 3,559 | 1,460,718 (3%) | 0% | 2.5 | 8,826 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 88,333 | 88,333 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 29,149 | 1,468,342 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 29,149 | 59,184 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Jan 2025 | 13,532 | 1,454,810 (3%) | 0% | 2.5 | 33,559 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 9,467 | 1,443,097 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 9,467 | 37,867 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Jan 2025 | 3,904 | 1,439,193 (3%) | 0% | 2.5 | 9,682 | Common Stock |
| Aclaris Therapeutics Inc | Walker Neal | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2024 | 118,840 | 0 | - | - | Employee Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | Walker Neal | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.52 per share. | 04 Dec 2024 | 118,840 | 1,501,973 (3%) | 0% | 1.5 | 180,637 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 04 Dec 2024 | 68,343 | 1,433,630 (3%) | 0% | 3.8 | 256,970 | Common Stock |
| Aclaris Therapeutics Inc | Walker Neal | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 9,466 | 47,334 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 9,466 | 1,385,854 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Walker Neal | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.07 per share. | 01 Dec 2024 | 2,721 | 1,383,133 (3%) | 0% | 4.1 | 11,074 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,467 | 56,800 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,467 | 1,379,109 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 01 Nov 2024 | 2,721 | 1,376,388 (3%) | 0% | 2.1 | 5,687 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 9,467 | 1,372,364 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 9,467 | 66,267 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 01 Oct 2024 | 2,722 | 1,369,642 (3%) | 0% | 1.2 | 3,212 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 9,466 | 1,365,619 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 9,466 | 75,734 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 01 Sep 2024 | 2,722 | 1,362,897 (3%) | 0% | 1.2 | 3,212 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.72 per share. | 09 Aug 2024 | 43,548 | 1,356,153 (3%) | 0% | 0.7 | 31,355 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 43,548 | 0 | - | - | Employee Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 9,467 | 85,200 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 9,467 | 1,315,327 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.32 per share. | 01 Aug 2024 | 2,722 | 1,312,605 (3%) | 0% | 1.3 | 3,593 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 9,467 | 94,667 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 9,467 | 1,308,582 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 01 Jul 2024 | 2,722 | 1,305,860 (3%) | 0% | 1.1 | 3,130 | Common Stock |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 40,282 | 40,282 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 1,736 | 1,736 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 9,466 | 1,301,837 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 9,466 | 104,134 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.03 per share. | 01 Jun 2024 | 2,722 | 1,299,115 (3%) | 0% | 1.0 | 2,804 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 9,467 | 113,600 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 9,467 | 1,295,155 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 01 May 2024 | 2,784 | 1,292,371 (3%) | 0% | 1.3 | 3,508 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 9,467 | 1,288,912 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 9,467 | 123,067 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 01 Apr 2024 | 3,224 | 1,285,688 (3%) | 0% | 1.3 | 4,062 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, Interim President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 9,466 | 1,282,668 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, Interim President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 9,466 | 132,534 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, Interim President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 3,223 | 1,279,445 (3%) | 0% | 1.2 | 3,997 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 497,000 | 497,000 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 142,000 | 142,000 | - | - | Restricted Stock Units | |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.55 per share. | 22 Aug 2023 | 9,604 | 15,854 (0%) | 0% | 0.6 | 5,301 | Common Stock |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2023 | 9,604 | 0 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 21,222 | 21,222 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 915 | 915 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 96,150 | 1,271,913 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 96,150 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 12.63 per share. | 01 Mar 2023 | 30,240 | 1,273,202 (3%) | 0% | 12.6 | 382,070 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 12.37 per share. | 01 Mar 2023 | 29,000 | 1,285,188 (3%) | 0% | 12.4 | 358,588 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 24,000 | 72,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 24,000 | 1,314,188 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 18,275 | 1,290,188 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 18,275 | 36,550 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 18,254 | 1,303,442 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 18,254 | 18,254 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 16.75 per share. | 01 Feb 2023 | 25,000 | 1,180,763 (2%) | 0% | 16.7 | 418,675 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 16.88 per share. | 01 Feb 2023 | 3,121 | 1,175,963 (2%) | 0% | 16.9 | 52,691 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 14.57 per share. | 01 Feb 2023 | 1,079 | 1,179,684 (2%) | 0% | 14.6 | 15,718 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 15.55 per share. | 01 Feb 2023 | 600 | 1,179,084 (2%) | 0% | 15.6 | 9,332 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 17.54 per share. | 01 Feb 2023 | 200 | 1,175,763 (2%) | 0% | 17.5 | 3,507 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 15.19 per share. | 03 Jan 2023 | 23,382 | 1,222,381 (2%) | 0% | 15.2 | 355,067 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 14.89 per share. | 03 Jan 2023 | 15,000 | 1,205,763 (2%) | 0% | 14.9 | 223,343 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director | Sale of securities on an exchange or to another person at price $ 16.16 per share. | 03 Jan 2023 | 1,618 | 1,220,763 (2%) | 0% | 16.2 | 26,146 | Common Stock |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 53,812 | 53,812 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 2,319 | 2,319 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.24 per share. | 21 Apr 2022 | 25,000 | 1,290,763 (3%) | 0% | 15.2 | 380,948 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 21 Apr 2022 | 25,000 | 1,265,763 (3%) | 0% | 15.0 | 376,098 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.18 per share. | 21 Apr 2022 | 20,000 | 1,245,763 (2%) | 0% | 15.2 | 303,656 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 11 Mar 2022 | 56,303 | 1,315,763 (3%) | 0% | 15.9 | 896,045 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 336,100 | 336,100 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 96,150 | 96,150 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 96,150 | 1,335,537 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 96,000 | 96,000 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 18,275 | 1,353,812 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 18,275 | 54,825 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 18,254 | 36,508 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 18,254 | 1,372,066 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 10,800 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 10,800 | 1,242,982 (2%) | 0% | - | Common Stock | |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 13,534 | 13,534 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Neal Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 583 | 583 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 73,015 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 73,015 | 1,265,442 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 01 Jun 2021 | 27,743 | 1,237,699 (2%) | 0% | 21.5 | 596,696 | Common Stock |
| Aclaris Therapeutics Inc | Neal Walker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.30 per share. | 01 Jun 2021 | 5,517 | 1,232,182 (2%) | 0% | 22.3 | 123,038 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges